Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer (NYSE: PFE) and Astellas announced Phase 3 EV-304 results showing perioperative PADCEV plus Keytruda cut risk of recurrence/progression or death by 47% versus neoadjuvant gemcitabine+ciplatin (HR 0.53; 95% CI 0.41–0.70; 1-sided p<.0001).
Two‑year event‑free survival was estimated at 79.4% versus 66.2%; overall survival improved (HR 0.65; 95% CI 0.48–0.89; 1-sided p=0.0029) and pathological complete response reached 55.8% versus 32.5% at surgery.
ViiV Healthcare (related to PFE) presented Phase 1 and in-vitro pipeline data at CROI 2026 showing two investigational long-acting HIV therapies with potential for twice-yearly dosing.
VH184, a third-generation INSTI, showed single-dose drug levels up to six months and improved resistance profile versus bictegravir. VH499, a capsid inhibitor, was generally well tolerated and supports ultra long-acting six-month dosing; phase 2b and further studies will define dosing.
ViiV Healthcare (PFE) reported 12-month interim Phase IIb EMBRACE data showing a regimen of intravenous lotivibart (N6LS) every four months plus monthly long-acting cabotegravir maintained viral suppression in 94% (IV) and 82% (SC) of participants versus 88% on standard of care.
The study observed confirmed virologic failures of 4% (n=2/50) IV, 6% (n=3/49) SC, and 4% (n=1/26) standard of care, with lotivibart generally well tolerated and the trial progressing to evaluate a twice-yearly IV dosing interval.
Pfizer (NYSE: PFE) announced FDA full approval (Feb 24, 2026) for BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for first-line BRAF V600E metastatic colorectal cancer after Phase 3 BREAKWATER results.
Phase 3 mFOLFOX6 data showed a 51% reduction in risk of death and 47% reduction in risk of progression or death versus chemotherapy ± bevacizumab; safety was consistent with known profiles.
Pfizer (NYSE: PFE) invites the public to a webcast of a discussion with Chairman and CEO Albert Bourla at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 10:30 a.m. EST.
Registration and access details are available at www.pfizer.com/investors. The transcript and replay will be posted within 24 hours and remain accessible for at least 90 days.
PFE-linked ViiV Healthcare reported final 48-week LATITUDE results showing long-acting injectable cabotegravir + rilpivirine cut cumulative regimen-failure risk nearly in half versus daily oral ART (22.8% vs 41.2%).
VF rates were 6.8% vs 28.2%; treatment-related failure 8.9% vs 28.1%; safety profiles were similar, with injection-site reactions most common.
ViiV Healthcare (PFE) will present clinical and real-world data at CROI 2026 highlighting ultra long‑acting (ULA) HIV candidates and established long‑acting therapies.
Key items include first‑in‑human VH184 long‑acting formulation data, 12‑month maintenance results for lotivibart (N6LS)+cabotegravir LA, VH499 capsid inhibitor dosing analyses, and expanded Cabenuva and CAB LA prevention evidence.
Pfizer (NYSE: PFE) reported that the BREAKWATER trial Cohort 3 showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for BRAFTOVI (encorafenib) plus cetuximab and FOLFIRI versus FOLFIRI ± bevacizumab in untreated BRAF V600E metastatic colorectal cancer.
Overall survival also showed clinically meaningful prolonged improvement; objective response rate was positive and presented at ASCO GI 2026. Safety was consistent with known profiles and no new signals were identified. The regimen remains investigational and will be submitted to FDA to support potential approval.
PROTAC market (coverage: 7MM) is forecast to grow sharply through 2034 as targeted protein degradation advances across oncology and other indications. Key pipeline assets include vepdegestrant, luxdegalutamide, ASP3082, and DT2216. The report cites ~90 protein-degradation leads, ~20% in clinical development, and PROTACs representing >30% of the protein degradation pipeline. Strategic partnerships include Arvinas collaborations with Pfizer and Novartis, and a Novartis up-front payment of USD 150 million for ARV-766 rights. Notable trial data: Phase III VERITAC-2 met its ESR1m primary endpoint but not the ITT population.
Pfizer (NYSE: PFE) announced the FDA has accepted and granted Priority Review for the supplemental BLA for HYMPAVZI (marstacimab) to expand use to patients ≥6 years with hemophilia A or B with inhibitors and children 6–11 years without inhibitors.
The FDA set a PDUFA action date in Q2 2026 and previously granted Breakthrough Therapy for prophylaxis in pediatric hemophilia B. Submissions rely on Phase 3 BASIS and BASIS KIDS trial data.